KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Non-Current Deffered Revenue for 18 consecutive years, with $225.1 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue rose 6.28% year-over-year to $225.1 million; the TTM value through Mar 2026 reached $225.1 million, up 6.28%, while the annual FY2025 figure was $208.7 million, 12.39% up from the prior year.
  • Non-Current Deffered Revenue hit $225.1 million in Q1 2026 for Regeneron Pharmaceuticals, up from $208.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $225.1 million in Q1 2026 and bottomed at $33.5 million in Q1 2022.
  • Average Non-Current Deffered Revenue over 5 years is $148.9 million, with a median of $185.7 million recorded in 2024.
  • Year-over-year, Non-Current Deffered Revenue decreased 4.77% in 2022 and then surged 155.22% in 2023.
  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue stood at $69.8 million in 2022, then surged by 81.52% to $126.7 million in 2023, then skyrocketed by 46.57% to $185.7 million in 2024, then rose by 12.39% to $208.7 million in 2025, then grew by 7.86% to $225.1 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $225.1 million, $208.7 million, and $219.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.